DocWire News Editors

DocwireNews

Patients with type 2&nbsp;<a class="Hyperlink SCXW251034824" href="https://proddocwire.wpengine.com/cardiology/4794553/" target="_blank" rel="noopener noreferrer">diabetes</a>&nbsp;who improve several&nbsp;risk factors&nbsp;saw&nbsp;a reduction in the risk of death, myocardial infarction, or stroke, a new study in the&nbsp;New England Journal of Medicine&nbsp;reported.&nbsp;Researchers for the study included 271,174 patients with type 2 diabetes and matched them with 1,355,870 matched controls. The authors specifically focused on 5 risk factors in patients with diabetes: elevated glycated hemoglobin levels, elevated LDL-C level, albuminuria,&nbsp;<a class="Hyperlink SCXW120289400" href="https://proddocwire.wpengine.com/cardiology/study-100-smoke-free-policies-yield-lower-cvd-risk/" target="_blank" rel="noopener noreferrer">smoking,</a>&nbsp;and elevated blood pressure. They used Cox regression models to evaluate excess risk of outcomes and looked at the relationship between the risk factors and cardiovascular outcomes.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Patients with type 2 diabetes who had five risk-factor variables within the target ranges appeared to have little or no excess risk of death, myocardial infarction, or stroke, as compared with the general population. Learn more: <a href="https://t.co/gURQcykvvg">https://t.co/gURQcykvvg</a> <a href="https://t.co/NuVbqKgjxQ">pic.twitter.com/NuVbqKgjxQ</a>
&mdash; NEJM (@NEJM) <a href="https://twitter.com/NEJM/status/1029841430423003141?ref_src=twsrc%5Etfw">August 15, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>According to the results, the excess risk of outcomes decreased for each factor that was brought to&nbsp;within&nbsp;target range. In&nbsp;patients&nbsp;who brought all five risk factors into range, hazard ratios were 1.06 (95% CI, 1.00 to 1.12) for death from any cause, 0.84 (95% CI, 0.75 to 0.93) for myocardial infarction, and 0.95 (95% CI, 0.84 to 1.07) for stroke. Risk for hospitalization due to heart failure was higher in patients with diabetes. Smoking was the strongest predictor of death, and glycated hemoglobin levels outside of target range were the strongest predictors of stroke.&nbsp;&nbsp;&ldquo;Patients with type 2 diabetes who had five risk-factor variables within the target ranges appeared to have little or no excess risk of death, myocardial infarction, or stroke, as compared with the general population,&rdquo; the researchers wrote in their abstract.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Excess risk of heart failure with diabetes, even if all 5 risk factors were at target levels. Role for SGLT2 inhibitors to address this risk?
&mdash; Gregg Fonarow MD (@gcfmd) <a href="https://twitter.com/gcfmd/status/1029850158647758848?ref_src=twsrc%5Etfw">August 15, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Why HDL and TG were not part of the risk factors analysis?
&mdash; Jasmin Levallois, MD (@jlevallois) <a href="https://twitter.com/jlevallois/status/1029898231055040513?ref_src=twsrc%5Etfw">August 16, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Rawshani brothers at it again. Brilliant minds! Pride and joy of the Sahlgrenska Academy.
&mdash; Gustaf L (@GotPed) <a href="https://twitter.com/GotPed/status/1029855232895995904?ref_src=twsrc%5Etfw">August 15, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Source: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1800256">New England Journal of Medicine</a>&nbsp;

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Improving Risk Factors May Cut Risk of Cardiovascular Outcomes, Mortality

Cardiology

Patients with type 2 diabetes who improve several risk factors saw a reduction in the risk of death, myocardial infarction, or stroke, a new study in the New England ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe